Published in Small on May 28, 2014
Biomimetic collagenous scaffold to tune inflammation by targeting macrophages. J Tissue Eng (2016) 0.79
A nanofibrous electrospun patch to maintain human mesenchymal cell stemness. J Mater Sci Mater Med (2017) 0.76
Composite microsphere-functionalized scaffold for the controlled release of small molecules in tissue engineering. J Tissue Eng (2016) 0.76
Patterning Biomaterials for the Spatiotemporal Delivery of Bioactive Molecules. Front Bioeng Biotechnol (2016) 0.75
Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model. Biol Open (2016) 0.75
Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat Biotechnol (2005) 13.90
A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J (2011) 10.70
Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev (1997) 5.73
Exploring and engineering the cell surface interface. Science (2005) 5.54
PLGA-based nanoparticles: an overview of biomedical applications. J Control Release (2012) 4.39
Extracellular matrix as a biological scaffold material: Structure and function. Acta Biomater (2008) 4.36
Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nanotechnol (2008) 3.78
Porous silicon in drug delivery devices and materials. Adv Drug Deliv Rev (2008) 3.43
Interactions between extracellular matrix and growth factors in wound healing. Wound Repair Regen (2009) 2.83
Design and analysis of tissue engineering scaffolds that mimic soft tissue mechanical anisotropy. Biomaterials (2006) 2.40
The enhancement of osteogenesis by nano-fibrous scaffolds incorporating rhBMP-7 nanospheres. Biomaterials (2007) 2.14
Collagen sponges for bone regeneration with rhBMP-2. Adv Drug Deliv Rev (2003) 2.13
FTIR microscopic imaging of collagen and proteoglycan in bovine cartilage. Biopolymers (2001) 2.07
Influence of freezing rate on pore structure in freeze-dried collagen-GAG scaffolds. Biomaterials (2004) 1.90
Tailored porous silicon microparticles: fabrication and properties. Chemphyschem (2010) 1.71
Is INFUSE bone graft superior to autograft bone? An integrated analysis of clinical trials using the LT-CAGE lumbar tapered fusion device. J Spinal Disord Tech (2003) 1.69
Fourier transform IR spectroscopy of collagen and gelatin solutions: deconvolution of the amide I band for conformational studies. Biopolymers (1988) 1.42
Chondrogenesis in a hyaluronic acid scaffold: comparison between chondrocytes and MSC from bone marrow and adipose tissue. Knee Surg Sports Traumatol Arthrosc (2009) 1.14
Gradient biomaterials for soft-to-hard interface tissue engineering. Acta Biomater (2011) 1.13
Design of graded biomimetic osteochondral composite scaffolds. Biomaterials (2008) 1.12
Engineering multi-stage nanovectors for controlled degradation and tunable release kinetics. Biomaterials (2013) 1.03
A highly organized three-dimensional alginate scaffold for cartilage tissue engineering prepared by microfluidic technology. Biomaterials (2011) 0.98
Low dose BMP-2 treatment for bone repair using a PEGylated fibrinogen hydrogel matrix. Biomaterials (2013) 0.96
Nanoscale structure of type I collagen fibrils: quantitative measurement of D-spacing. Biotechnol J (2012) 0.96
The role of ECM proteins and protein fragments in guiding cell behavior in regenerative medicine. Biomaterials (2011) 0.95
Porous hydroxyapatite scaffold with three-dimensional localized drug delivery system using biodegradable microspheres. J Control Release (2011) 0.94
Multimodal release of transforming growth factor-β1 and the BB isoform of platelet derived growth factor from PEGylated fibrin gels. J Control Release (2010) 0.93
High-porosity poly(epsilon-caprolactone)/mesoporous silicon scaffolds: calcium phosphate deposition and biological response to bone precursor cells. Tissue Eng Part A (2008) 0.92
Gelatin/chitosan/hyaluronan scaffold integrated with PLGA microspheres for cartilage tissue engineering. Acta Biomater (2008) 0.92
Controlled release strategies for bone, cartilage, and osteochondral engineering--Part II: challenges on the evolution from single to multiple bioactive factor delivery. Tissue Eng Part B Rev (2013) 0.90
Evaluation of cell function upon nanovector internalization. Small (2012) 0.87
A novel method for the direct fabrication of growth factor-loaded microspheres within porous nondegradable hydrogels: controlled release for cartilage tissue engineering. J Control Release (2011) 0.86
Slow-release human recombinant bone morphogenetic protein-2 embedded within electrospun scaffolds for regeneration of bone defect: in vitro and in vivo evaluation. Tissue Eng Part A (2010) 0.85
Agarose surface coating influences intracellular accumulation and enhances payload stability of a nano-delivery system. Pharm Res (2011) 0.84
The role of nanostructured mesoporous silicon in discriminating in vitro calcification for electrospun composite tissue engineering scaffolds. Nanoscale (2010) 0.83
BMP-7-loaded PGLA microspheres as a new delivery system for the cultivation of human chondrocytes in a collagen type I gel: the common nude mouse model. Int J Artif Organs (2010) 0.81
A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J (2011) 10.70
Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nanotechnol (2008) 3.78
Intravascular delivery of particulate systems: does geometry really matter? Pharm Res (2008) 3.13
Clinical proteomics: written in blood. Nature (2003) 2.81
Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res (2010) 2.80
Nanomedicine--challenge and perspectives. Angew Chem Int Ed Engl (2009) 2.74
Nanotechnologies for biomolecular detection and medical diagnostics. Curr Opin Chem Biol (2006) 2.74
Seven challenges for nanomedicine. Nat Nanotechnol (2008) 2.59
Cancer risk after use of recombinant bone morphogenetic protein-2 for spinal arthrodesis. J Bone Joint Surg Am (2013) 2.19
Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T1 contrast. Nat Nanotechnol (2010) 2.17
Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol (2012) 1.85
A challenge to integrity in spine publications: years of living dangerously with the promotion of bone growth factors. Spine J (2011) 1.73
Design maps for nanoparticles targeting the diseased microvasculature. Biomaterials (2007) 1.72
Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. J Control Release (2011) 1.72
Tailored porous silicon microparticles: fabrication and properties. Chemphyschem (2010) 1.71
Shaping nano-/micro-particles for enhanced vascular interaction in laminar flows. Nanotechnology (2009) 1.63
The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. Biomaterials (2009) 1.63
What does physics have to do with cancer? Nat Rev Cancer (2011) 1.59
Morphologic instability and cancer invasion. Clin Cancer Res (2005) 1.55
Nanogeometry: beyond drug delivery. Nat Nanotechnol (2008) 1.54
Prediction of drug response in breast cancer using integrative experimental/computational modeling. Cancer Res (2009) 1.53
Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells. PLoS One (2010) 1.49
Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation. J Math Biol (2008) 1.48
Osmotic pressure beyond concentration restrictions. J Phys Chem B (2007) 1.46
Biotechnology apprenticeship for secondary-level students: teaching advanced cell culture techniques for research. Cell Biol Educ (2002) 1.45
Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc Chem Res (2011) 1.45
Hesperetin impairs glucose uptake and inhibits proliferation of breast cancer cells. Cell Biochem Funct (2012) 1.44
T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc Natl Acad Sci U S A (2003) 1.37
Antibiological barrier nanovector technology for cancer applications. Expert Opin Drug Deliv (2007) 1.36
Integrated intravital microscopy and mathematical modeling to optimize nanotherapeutics delivery to tumors. AIP Adv (2012) 1.35
Discoidal Porous Silicon Particles: Fabrication and Biodistribution in Breast Cancer Bearing Mice. Adv Funct Mater (2012) 1.35
Mitotic trafficking of silicon microparticles. Nanoscale (2009) 1.35
A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep (2013) 1.33
Cellular association and assembly of a multistage delivery system. Small (2010) 1.32
Biodegradable porous silicon barcode nanowires with defined geometry. Adv Funct Mater (2010) 1.31
Tailoring the degradation kinetics of mesoporous silicon structures through PEGylation. J Biomed Mater Res A (2010) 1.31
Mathematical modeling of cancer progression and response to chemotherapy. Expert Rev Anticancer Ther (2006) 1.30
Multiparameter computational modeling of tumor invasion. Cancer Res (2009) 1.28
Enabling individualized therapy through nanotechnology. Pharmacol Res (2010) 1.28
Nanomedicine in cancer therapy: innovative trends and prospects. Cancer Sci (2011) 1.27
Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest (2014) 1.26
The preferential targeting of the diseased microvasculature by disk-like particles. Biomaterials (2012) 1.25
Interstitial stress and fluid pressure within a growing tumor. Ann Biomed Eng (2003) 1.25
Multi-stage delivery nano-particle systems for therapeutic applications. Biochim Biophys Acta (2010) 1.23
Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases. Trends Pharmacol Sci (2010) 1.22
Intrinsic magnetism and hyperthermia in bioactive Fe-doped hydroxyapatite. Acta Biomater (2011) 1.22
Biologically inspired synthesis of bone-like composite: self-assembled collagen fibers/hydroxyapatite nanocrystals. J Biomed Mater Res A (2003) 1.21
Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin Cancer Res (2013) 1.21
Logic-embedded vectors for intracellular partitioning, endosomal escape, and exocytosis of nanoparticles. Small (2010) 1.19
Identification of thioaptamer ligand against E-selectin: potential application for inflamed vasculature targeting. PLoS One (2010) 1.19
Cooperative, nanoparticle-enabled thermal therapy of breast cancer. Adv Healthc Mater (2011) 1.16
Quantitative mechanics of endothelial phagocytosis of silicon microparticles. Cytometry A (2009) 1.16
Tailoring of the nanotexture of mesoporous silica films and their functionalized derivatives for selectively harvesting low molecular weight protein. ACS Nano (2010) 1.16
Design of bio-mimetic particles with enhanced vascular interaction. J Biomech (2009) 1.15
Intracellular trafficking of silicon particles and logic-embedded vectors. Nanoscale (2010) 1.15
Orderly osteochondral regeneration in a sheep model using a novel nano-composite multilayered biomaterial. J Orthop Res (2010) 1.14
Laparoscopic treatment of splenic artery aneurysms. J Vasc Surg (2009) 1.13
E-selectin-targeted porous silicon particle for nanoparticle delivery to the bone marrow. Adv Mater (2011) 1.12
Design of graded biomimetic osteochondral composite scaffolds. Biomaterials (2008) 1.12
Nanotechnology for breast cancer therapy. Biomed Microdevices (2009) 1.10
Sr-substituted hydroxyapatites for osteoporotic bone replacement. Acta Biomater (2007) 1.09
Mesoporous silica chips for selective enrichment and stabilization of low molecular weight proteome. Proteomics (2010) 1.08
Adult and umbilical cord blood-derived platelet-rich plasma for mesenchymal stem cell proliferation, chemotaxis, and cryo-preservation. Biomaterials (2012) 1.07
Human lung cancer cells grown in an ex vivo 3D lung model produce matrix metalloproteinases not produced in 2D culture. PLoS One (2012) 1.07
The transport of nanoparticles in blood vessels: the effect of vessel permeability and blood rheology. Ann Biomed Eng (2008) 1.07
Novel human-derived cell-penetrating peptides for specific subcellular delivery of therapeutic biomolecules. Biochem J (2005) 1.07
Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment. Cancer Lett (2012) 1.06
Thioaptamer conjugated liposomes for tumor vasculature targeting. Oncotarget (2011) 1.06
Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy. Small (2013) 1.05
Near-infrared imaging method for the in vivo assessment of the biodistribution of nanoporous silicon particles. Mol Imaging (2011) 1.04
Nanotechnology and tumor imaging: seizing an opportunity. Mol Imaging (2004) 1.04
Engineering multi-stage nanovectors for controlled degradation and tunable release kinetics. Biomaterials (2013) 1.03
Recommendations of the National Heart, Lung, and Blood Institute Nanotechnology Working Group. Circulation (2003) 1.02
Treatment of lumbar disc herniation: Evidence-based practice. Int J Gen Med (2010) 1.02
Magnetic hydroxyapatite bone substitutes to enhance tissue regeneration: evaluation in vitro using osteoblast-like cells and in vivo in a bone defect. PLoS One (2012) 1.02
Enhanced MRI relaxivity of Gd(3+) -based contrast agents geometrically confined within porous nanoconstructs. Contrast Media Mol Imaging (2012) 1.02
Tailoring width of microfabricated nanochannels to solute size can be used to control diffusion kinetics. J Control Release (2005) 1.02
Biomimetic Mg-substituted hydroxyapatite: from synthesis to in vivo behaviour. J Mater Sci Mater Med (2007) 1.00
An integrated approach for the rational design of nanovectors for biomedical imaging and therapy. Adv Genet (2010) 1.00
A biologic without guidelines: the YODA project and the future of bone morphogenetic protein-2 research. Spine J (2012) 1.00